Tumors elude anti-cancer drugs through 'fork reversal' repair

Aug 06, 2013
Tumors elude anti-cancer drugs through 'fork reversal' repair
Representative electron micrograph showing the image of a reversed replication fork. D, daughter strand; P, parental strand; R, reversed arm.  

In research recently published in Nature Structural & Molecular Biology, Alessandro Vindigni, Ph.D., associate professor of biochemistry and molecular biology at Saint Louis University, discovered how cancer cells respond to the damage caused by an important class of anti-cancer drugs, topoisomerase I inhibitors. The discovery points to opportunities to improve chemotherapeutic regimens based on topoisomerase I inhibitor treatment and limit their toxic side effects.

"Most cancer chemotherapeutics act by inhibiting DNA replication," Vindigni said. "The drugs aim to target highly proliferating rather than normal cells, but unfortunately many also are toxic for normal cells."

Cells, both healthy and cancerous, reproduce by replicating their DNA. Anti-cancer drugs like topoisomerase I (TOP1) inhibitors work by disrupting DNA replication in cancer cells.

As a cell's double helix-shaped DNA strands split apart and begin to copy themselves, the long strands get wound up, like a rope that's been twisted too many times. The coils must be released or replication can't continue to move forward. Topoisomerase is an enzyme that temporarily cuts the rope of DNA, lets it untwist, and puts it back together again. If you block this process with a TOP1 inhibitor, the rope remains knotted and cell duplication stops.

Scientists' understanding of how TOP1 inhibitors work has, however, been incomplete. The working theory has been that TOP1 inhibitors leave a nick on one of the DNA strands by inhibiting the ability of the topoisomerase to seal the broken DNA. When the replication machinery collides with this nick, a double strand break occurs which stops the replication process. Double strand breaks are the worst kind of DNA lesions because both strands are compromised and require a complicate DNA repair pathway to be fixed.

In his recent findings, however, Vindigni and his team found that the cells are much "smarter" than they originally appeared.

Living up to their crafty reputation, cancer cells have a strategy to deal with this scenario. When TOP1 inhibition causes "replication stress" in the form of a nick on the DNA, the replication machinery pauses and reverses its course instead of colliding with the TOP1 induced DNA lesion. This mechanism of "replication fork reversal" gives time for the lesion to be repaired, so that replication can continue on again, preventing the hoped-for double strand break.

In fact, not only does the strand halt when it reaches the nick, but it senses the problem ahead of time, coming down the line. The replication structure does not operate blindly, but has advance notice of the injury, which gives it time to halt and repair the lesion before it reverses course and move into forward gear again.

"This is important because it is the first evidence that says that cancer cells' DNA replication machinery can react to drug treatment through fork reversal. Now we also uncovered the mechanism to restart the replication forks."

Vindigni's team also found that two important cellular proteins, PARP and RECQ1, control the fork reversal mechanism.

In particular, RECQ1, which is an enzyme that plays a key role in the maintenance of genome stability, appears to be responsible for restarting the reversed replication forks once the TOP1 induced lesion has been repaired. The reversed forks cannot restart without the help of RECQ1, suggesting it may be a promising target for a drug therapy.

Once they undercut the replication fork reversal process, researchers can return to the approach of encouraging a "fatal" double strand break for cancer cells by combing TOP1 inhibitors with novel inhibitors of the proteins that control the process of replication fork reversal and restart. In addition, inducing replication fork reversal by TOP1 inhibitor treatment and impeding reversed replication fork restart by RECQ1 inhibition should also stop DNA replication, thus allowing doctors to use lower TOP1 inhibitor doses, which, in turn, would mean fewer side effects.

What's next?

Researchers' next step is to determine if this mechanism holds true not just in response to TOP1 inhibitors, but also with other cancer drugs, a finding that would broaden this paper's significance even further.

Another important step will be to search for other factors that control the reversal process, findings which would offer additional opportunities to disrupt the process.

"TOP1 drugs are widely used in clinic for many types of cancer. However, they also are highly toxic," Vindigni said. "We discovered the mechanism that the cancer cells' machinery uses to respond to treatment with these drugs. We also discovered the factors that control this mechanism.

"We hope to combine new RECQ1 inhibitors with existing drugs to create more effective and specific therapies with fewer toxic side effects."

Explore further: 'Cowcatcher' enzyme fixes single-strand DNA

More information: www.nature.com/nsmb/journal/v2… /full/nsmb.2501.html

Related Stories

How chemotherapy becomes more effective

Mar 05, 2012

Researchers from the University of Zurich have found a cellular brake that protects cancer cells from chemotherapy -- and they demonstrate which medication can be used to render it inoperative. Their study published in the ...

'Cowcatcher' enzyme fixes single-strand DNA

Jul 29, 2013

Every time one of your cells divides, it exposes its most essential component to great danger: its genome, the sum total of all its genetic information, embodied in the double-stranded helix of DNA. Prior to cell division, ...

Some cells don't know when to stop

Nov 19, 2012

Certain mutated cells keep trying to replicate their DNA—with disastrous results—even after medications rob them of the raw materials to do so, according to new research from USC.

Dual systems key to keeping chromosomes intact

Mar 07, 2013

USC scientists have discovered how two different structural apparatuses collaborate to protect repetitive DNA when it is at its most vulnerable – while it is being unzipped for replication.

Recommended for you

Researchers uncover secrets of internal cell fine-tuning

9 hours ago

New research from scientists at the University of Kent has shown for the first time how the structures inside cells are regulated – a breakthrough that could have a major impact on cancer therapy development.

Microscopic rowing—without a cox

10 hours ago

Many different types of cell, including sperm, bacteria and algae, propel themselves using whip-like appendages known as flagella. These protrusions, about one-hundredth of a millimetre long, function like ...

Illuminating the dark side of the genome

16 hours ago

Almost 50 percent of our genome is made up of highly repetitive DNA, which makes it very difficult to be analysed. In fact, repeats are discarded in most genome-wide studies and thus, insights into this part ...

User comments : 0